Tag: australia

older elderly senior citizen seniors

Australian Researchers Find Cannabis Oils To Be Effective For Symptom Management In Older Patients

Neurological disorders affect many people around the globe. In fact, it is estimated that as many as 1 billion people across the globe suffer from some type of neurological disorder. People over 50 years old are more likely to develop a neurological condition compared to younger people.

Neurological disorders are diseases that affect the central and peripheral nervous systems, including the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles.

Various pharmaceutical medications are regularly prescribed to help address symptoms of neurological conditions among elderly patients. Just as symptoms are wide-ranging, so too are the medications. One medication that is showing promise is cannabis, as demonstrated in a recent study out of Australia. Below is more information about it via a news release from NORML:

Sydney, Australia: The use of plant-derived cannabis oils containing balanced ratios of THC and CBD is generally safe and effective for patients suffering from neurological diseases, according to observational trial data published in the Journal of Clinical Medicine.

Australian researchers assessed the sustained use of cannabis extracts in 157 patients with treatment-resistant neurological, musculoskeletal, autoimmune, or anti-inflammatory disorders. (Under Australian law, physicians may only authorize medical cannabis to patients that have been unresponsive to conventional prescription treatments.)

Investigators reported that patients age 65 or older and/or those suffering from neurological disorders, such as Parkinson’s disease, peripheral neuropathy, and multiple sclerosis, perceived the greatest overall benefits from cannabis therapy. Their findings are consistent with those of several other studies reporting health-related quality of life benefits among older patients who consume cannabis.

Subjects were most likely to report cannabis to be effective for improving sleep and for reducing pain – findings that are consistent with other studies. By contrast, patients suffering from spondylosis were least likely to perceive benefits from cannabis therapy.

Authors concluded: “This retrospective medical record review describes the population characteristics of patients using medicinal cannabis at a clinic in Sydney, Australia and provides data on the effectiveness and safety of medicinal cannabis treatment on patient conditions and indications. … [Its findings] indicate that medicinal cannabis, in a balanced formulation, may address a variety of non-cancer conditions and indications concurrently and can be safely prescribed by a medical doctor.”

Full text of the study, “A retrospective medical record review of adults with non-cancer diagnoses prescribed medical cannabis,” appears in the Journal of Clinical Medicine. Additional information on cannabis use among older populations is available from NORML Fact Sheet ‘Cannabis Use by Older Populations.’


australia flag

Calls For Cannabis Reform Are Picking Up Steam In Australia

Back in February, Australia‘s Parliamentary Budget Office (PBO) released a report that presented two options for legalizing adult-use cannabis in Australia. The first option involves the creation of a new entity, the Cannabis National Agency. The agency would be the sole wholesaler between producers and licensed retailers, and it would set wholesale prices and issue all licenses.

Under the first option, the legal age for adult-use cannabis would be 18. Additionally, adult households would be able to cultivate up to six plants, and legal sales via licensed retailers would be permitted for non-residents in addition to residents.

All licensed sales would be “subject to the Goods and Services Tax (GST) as well as a 25% excise duty on sales including the GST”. The second option that was part of the PBO report contains all of the previously mentioned provisions, with the exception of a lower excise rate (15%).

Several lawmakers in Australia are touting the recommendations of the report, including Greens Senator David Shoebridge. Per The Guardian:

Australia’s cannabis industry could be earning the black market $25bn a year and, rather than policing it, we could be gaining revenue from it by legalising it, Greens senator David Shoebridge has said.

“Law enforcement is spending billions of public dollars failing to police cannabis, and the opportunity here is to turn that all on its head by legalising it,” he said.

Shoebridge indicated that he intends to introduce a legalization bill that will be somewhat modeled on Canada’s adult-use cannabis policies. Canada became the second country to legalize cannabis for adult use in 2018, with Uruguay being the first in 2013.

Unlike Uruguay, which limits legal sales to residents only, Canada permits legal sales through various licensed channels to anyone of legal age, regardless of what country they are a resident of. As such, Canada is a top international cannabis tourism destination. With any luck, Australia will join them.


sydney australia

Australia Cannabis Legalization Could Generate A$28 Billion In Tax Revenue In First Decade

A new government report is out in Australia involving projections of potential tax revenue if/when national adult-use cannabis legalization becomes a reality in the country. Adult-use is currently illegal in most areas of Australia, with a notable exception being the Australian Capital Territory where some legal protections for consumers exist.

Cannabis commerce, including medical cannabis commerce, is very restrictive in Australia. Most of the country’s medical cannabis industry activity currently revolves around pharmaceutical products and research.

Australia ‘s Parliamentary Budget Office recently released a report that presents two options for legalizing adult-use cannabis in Australia. Part of the report also includes projections for possible industry tax revenue. Per Newsfeed:

According to the PBO report , the first option calls for the creation of the Cannabis National Agency (CANA), which would act as the sole wholesaler between growers and retailers, set wholesale cannabis prices and issue licenses to potential cannabis owners. cannabis companies. Ideally, the agency would be funded entirely by production and retail licensing.

This option would legalize cannabis for anyone aged 18 and over, with no restrictions on how much a person can buy. This approach would also create penalties for selling to underage people, as with alcohol. Cannabis would be available to “overseas visitors”, and residents would be allowed to grow up to six plants. Finally, recreational sales would be “subject to the Goods and Services Tax (GST) as well as a 25% excise duty on sales including the GST”.

The second option contains all the provisions of the first option, except for the final recommendation, which would increase the excise tax to 15% instead of 25%.

The report estimates that legalization would generate as much as A$28 billion in the first ten years after a regulated adult-use industry was launched. It’s worth noting that the projected figure is largely based on a snapshot in time.

As the global cannabis industry continues to evolve and the landscape shifts, the profit potential for companies and governments will shift with it. That is true in Australia just as it is true everywhere else around the world.

It’s unclear at this time what the chances are of either option listed in the government report actually becoming law, but it is encouraging to see that multiple options are being considered, and that the information is from a government entity.


cannabis joint preroll

Cannabis Smoke Not Associated With Impaired Lung Function According To Australia Study

Cannabis opponents do their best to try to lump cannabis smoke and tobacco smoke into the same category, and to be fair, it’s something that many people accept unless they have looked at the body of research on the topic.

Anyone that has researched cannabis smoke versus tobacco smoke knows that they are not the same, and that tobacco smoke is demonstrably worse for consumers compared to cannabis smoke for various reasons.

A recent study conducted in Australia found that cannabis smoke exposure is not associated with impaired lung function among consumers. Below is more information about it via a news release from NORML:

South Brisbane, Australia: The long-term inhalation of cannabis smoke does not impact lung function in the same manner as inhaling tobacco, according to longitudinal data published in the journal Respiratory Medicine.

A team of Australian researchers evaluated the impact of tobacco smoking and cannabis smoking on lung function in a cohort of 30-year-old subjects. Study participants began smoking cannabis, tobacco, or both as young adults. Pulmonary performance was evaluated at age 21 and at age 30 via a spirometry assessment.

Researchers reported that cigarette-only smokers “already showed evidence of impaired lung function” at age 30. By contrast, “those who have [only] used cannabis ever since the adolescent period do not appear to have evidence of impairment of lung function.” Specifically, investigators identified airflow obstructions in the lungs of cigarette-only smokers, but they observed no such obstructions in cannabis-only subjects.

Authors further acknowledged, “Co-use of tobacco and cannabis does not appear to predict lung function beyond the effects of tobacco use alone.”

They concluded, “Cannabis use does not appear to be related to lung function even after years of use.”

The findings are consistent with those of numerous other studies reporting that cannabis smoke exposure, even long-term, is not predictive of the sort of significant adverse pulmonary effects that are consistently associated with tobacco.

Consumers who wish to mitigate or eliminate their exposure to combustive smoke may do so via an herbal vaporizer, which heats cannabinoids to the point of vaporization but below the point of combustion. In clinical trials, herbal vaporizers have been found to be a “safe and effective” cannabinoid delivery device.

Full text of the study, “Do tobacco and cannabis use and co-use predict lung function: A longitudinal study,” appears in Respiratory Medicine. Additional information is available from NORML’s Fact Sheet, ‘Cannabis Exposure and Lung Health.


bed rest nap sleep insomnia

Clinical Trial Finds Cannabis Oil To Be Effective At Treating Insomnia

Insomnia may not seem like a serious health condition to some people, however, anyone that suffers from significant insomnia will be quick to point out that it can have a negative impact on a person’s life.

The Mayo Clinic defines insomnia as, “a common sleep disorder that can make it hard to fall asleep, hard to stay asleep, or cause you to wake up too early and not be able to get back to sleep.” Chronic insomnia occurs when the condition lasts longer than a month.

In addition to making a person feel tired throughout the day, insomnia can also be an indicator of one or more other serious health conditions. Researchers in Australia recently conducted a clinical trial involving cannabis extracts and insomnia patients, and their findings are encouraging. Below is more information via a news release from NORML:

Melbourne, Australia: The short-term use of plant-derived cannabis extracts is well-tolerated and effective in patients diagnosed with insomnia, according to placebo-controlled trial data published in the Journal of Sleep Research.

Australian researchers assessed the use of a proprietary cannabis oil product (Entoura-10:15) versus placebo in 29 subjects with chronic insomnia. Extracts contained 10mg of THC and 15mg of CBD. Participants consumed either extracts or placebo for a period of two weeks.

Investigators reported that those receiving cannabis extracts experienced improved sleep quality by up to 80 percent, and that “60 percent of participants no longer classified as clinical insomniacs at the end of the two-week intervention period.”

They concluded: “Our short-term trial suggests Entoura 10:15 medicinal cannabis oil, containing THC:CBD 10:15 and lesser amounts of other CBs and naturally occurring terpenes, to be well tolerated and effective in significantly improving sleep quality and duration, midnight melatonin levels, quality of life, and mood within 2-weeks in adults with insomnia. … Long-term studies are needed to assess whether chronic medicinal cannabis intake can restore natural circadian rhythm without the need for ongoing cannabis intake.”

The results are similar to those of a prior placebo-controlled clinical trial, published in 2021, that also reported that plant-derived cannabis extracts are “well tolerated and improve insomnia symptoms and sleep quality in individuals with chronic insomnia symptoms.” Observational trials similarly report benefits in patients’ sleep quality following the inhalation of cannabis flowers prior to bedtime.

Full text of the study, “Medicinal cannabis improves sleep in adults with insomnia: A randomized double-blind placebo-controlled crossover trial,” appears in the Journal of Sleep Research. Additional information on cannabis and insomnia is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.

australia, insomnia


Researchers In Australia Find Oral Cannabis Products To Be Safe And Effective

Oral cannabis products have grown in popularity and availability in recent years. Many patients still prefer to consume medical cannabis in edible or inhaled form, however, some patients need to have smokeless options in forms that do not require chewing and other effort that is hard for some patients.

Many oral cannabis products have a long shelf life, are easy to transport and store, and provide a specific dosage of cannabinoids that many patients’ conditions and situations require. Oral cannabis products are not for every patient in every situation, yet they are a great option for many.

One lingering question that accompanies any new form of medicine is, ‘is it safe and effective?’ A team of researches in Australia recently explored the long-term safety and efficacy of oral cannabis products and the results were encouraging. Below is more information about it via a news release from NORML:

Western Australia, Australia: Patients authorized to consume plant-derived oral cannabis products show sustained improvements in their symptoms, according to longitudinal data published in the journal PLOS One.

Researchers assessed the long-terms safety and efficacy of oral cannabis products in a cohort of nearly 4,000 Australian patients authorized to use them. Study participants were naïve to cannabis prior to their enrollment in the trial. The majority of the study’s subjects (64 percent) suffered from chronic pain conditions. All of the study’s participants consumed oral cannabis products for a period of two years.

Investigators reported: “This is the largest and longest real-world analysis of the efficacy and safety of GMP [good manufacturing practices]-like oral medicinal cannabis (MC) in a continuous enrolment cohort registry. 3,961 heterogenous, cannabis naïve patients with a wide range of ages, clinical and complex conditions, and concomitant medications, prescribed oral MC, demonstrated a rapid and significant improvement across all measured patient and clinical reported validated outcomes. … Oral MC was well tolerated. … This safety is particularly salient in contrast to the safety and tolerability of prescribed long-term opioids.”

They concluded, “This large Australian longitudinal cohort registry of cannabis naïve, complex chronic disease patients treated with oral MC for over 24 consecutive months, demonstrates safety of oral generic medicinal cannabis, and demonstrated oral MC improves patient and clinician reported impact of pain, sleep and well-being.”

An estimated 100,000 Australians have been prescribed cannabis products following the enactment of legal changes in 2016 providing patients with regulatory access to medical marijuana products.

Full text of the study, “A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years,” appears in PLOS One.


cannabis joint preroll

Australian Researchers Find Lacking Evidence To Support Cannabis ‘Hangover’ Claims

When cannabis opponents speak out against cannabis they incorporate a variety of talking points, with some being more ridiculous than others. It seems as if some opponents will do or say just about anything to portray cannabis use in a negative fashion.

One argument that seems to be deployed at an increasing rate is that ‘cannabis causes hangovers.’ In an example of the sad hypocrisy that often accompanies anti-cannabis propaganda, very rarely, if ever, do those same cannabis opponents call for an end to alcohol sales due to hangovers.

Furthermore, while there is ample evidence that alcohol use can result in hangovers, researchers in Australia have found that the same is not true for cannabis, despite what cannabis opponents may claim. Below is more information about it via a news release from NORML:

New South Wales, Australia: The majority of available data fails to support claims that cannabis may potentially impact either cognitive function or subjects’ performance of safety sensitive tasks 24 hours after consumption, according to a review of the scientific literature published in the journal Cannabis and Cannabinoid Research.

A team of Australian researchers reviewed data from 20 studies involving 458 subjects. Selected studies assessed subjects’ performance 12 to 24 hours following THC dosing.

Investigators failed to identify any evidence of so-called THC-specific “next-day effects” in 16 of the 20 studies reviewed.

They concluded: “A small number of lower-quality studies have observed negative (i.e., impairing) ‘next day’ effects of THC on cognitive function and safety-sensitive tasks. However, higher-quality studies, and a large majority of performance tests, have not. Overall, it appears that there is limited scientific evidence to support the assertion that cannabis use impairs ‘next day’ performance.”

Authors further opined that the imposition of workplace drug testing policies that detect the long-term presence of cannabis metabolites and impose sanctions upon those who test positive for them are arguably not justified by the available data.

Full text of the study, “The ‘next day’ effects of cannabis use: A systematic review,” appears in Cannabis and Cannabinoid ResearchAdditional information is available in NORML’s fact sheet, ‘Marijuana Legalization and Impact on the Workplace.’


CBD oil

CBD Extract Autism Trial Results In Australia Are Encouraging

One of the most promising areas of cannabis research in recent years involves cannabidiol (CBD) and autism. A number of peer-reviewed studies have found that CBD can be an effective treatment for people diagnosed with autism, including children.

The topic of cannabis and children is unfortunately the target of significant stigma. To some degree, concern regarding cannabis and children is understandable given that some cannabinoids can yield psychoactive effects, however, CBD is not one of those.

Every suffering patient deserves to have safe access to effective forms of medicine, and that includes children and CBD if a medical professional and the children’s parents determine that CBD is part of a proper medication strategy. A recent study in Australia found promising results for CBD and children diagnosed with autism. Below is more information about it via a news release from NORML:

Melbourne, Australia: Children with autism spectrum disorder (ASD) show significant improvements in their symptoms following the use of plant-derived CBD dominant extracts, according to phase 1 trial results reported by Australian media.

Patients in the trial consumed extracts containing CBD and other non-THC phyto-cannabinoids twice daily for a period of at least two months. Researchers affiliated with the study said that patients experienced significant changes in communication and socialization skills, among other symptom improvements. Side-effects were minimal.

The findings are consistent with several other studies similarly reporting improvements in pediatric patients’ ASD symptoms following the use of cannabinoid products, particularly CBD-rich extracts. Survey data published in 2021 by Autism Parenting Magazine reported that 22 percent of US caregivers or parents have provided CBD to an autistic child. Survey data from the United Kingdom recently reported that autistic adults were nearly four times as likely as controls to report having used CBD within the past year.

Additional information on cannabis and ASD is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.


back pain

Cannabis Spray Shows Promise For Cancer Patients With Refractory Pain

One area of cannabis research that is of particular interest to people around the globe, and for obvious reasons, pertains to how the cannabis plant can be used to help people suffering from cancer. It’s one of the most intriguing, and yet also controversial topics in the cannabis world.

A growing body of peer-reviewed research is finding that the cannabis plant can help effectively treat cancer and related symptoms. It is important to differential between the claim that ‘cannabis can help treat cancer’ versus ‘cannabis cures cancer.’

Many personal patient experiences back up the claim that cannabis may cure cancer, in some instances. However, it is a very cruel thing to tell someone that is suffering from cancer that something, cannabis included, will absolutely cure their cancer, guaranteed. After all, nothing is ever guaranteed when it comes to medicine and treatment regimens.

More research needs to be conducted, and hopefully one day there is a cure found for cancer, and if the cure does indeed prove to involve cannabis, that would be amazing. Until that time, the cannabis plant can still do other things to help suffering cancer patients, including when it comes to pain management.

A recent study out of Australia examined a specific cannabis spray to see if it helped treat cancer patients experiencing refractory pain, and the results of the study are encouraging. Below is more information about it via a news release from NORML:

New South Wales, Australia: Terminal cancer patients with refractory pain respond favorably to a proprietary cannabis spray containing equal ratios of plant-derived THC and CBD, according to data published in the journal PLOS One.

A team of Australian investigators assessed the safety and efficacy of a novel water-soluble oro-buccal nanoparticle spray containing 2.5 mgs of THC and 2.5 mgs of CBD in a cohort of patients with advanced cancer and intractable pain.

Researchers reported that cannabis dosing was associated with improvements in pain relief among all patients, with those patients suffering from bone metastasis experiencing the greatest levels of relief. No serious adverse events were reported, though some patients did experience drowsiness following treatment.

Patients also reported improvements in appetite and emotional well-being.

“This study demonstrated that the administration of the investigative cannabis-based medicine was generally safe and tolerated in a short-term exposure in a cohort of patients with advanced incurable cancers with controlled pain or intractable pain despite opioid treatment,” authors concluded. “There was a reduction in pain overall for the study cohort of 12 percent by the end of the treatment phase. … [This] cannabis-based medicine … is of significant clinical interest given that this formulation was a self-titrated medicine, that showed preliminary analgesic efficacy in a subgroup of patients.”

Full text of the study, “Pilot clinical and pharmacokinetic study of delat-9-tetrahydrocannabinol/cannabidiol nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain,” appears in PLOS One. Additional information on cannabis for pain mitigation is available from NORML.



The Greens Urge Australia’s Federal Parliament To Legalize Adult-Use Cannabis

Australia is home to an emerging cannabis industry, although cannabis laws vary from state to state throughout the country. The most progressive region when it comes to cannabis policy can be found in the Australian Capital Territory (ACT), where cannabis was decriminalized in 2020.

In fact, as we previously reported, the University of Sydney is launching a free cannabis testing program for residents of ACT that want to test their cannabis. The goal of that program is to gather insight into what potencies and varieties of cannabis consumers are actually cultivating and/or consuming in Australia. That insight, in theory, will help lawmakers craft policies and regulations.

Leadership among The Australian Greens, or The Greens as the party is often referred to, is urging the nation’s government to legalize cannabis for adult use at the national level, and in the process, supersede any local prohibition policies. Per The Guardian:

As the minor party ramps up its campaign to legalise cannabis ahead of a planned private member’s bill to be introduced next year, the Greens’ justice spokesperson, David Shoebridge, said the advice from constitutional lawyer Patrick Keyzer paved the way for new federal laws.

The advice suggests that there are three commonwealth heads of power that would enable it to legalise and regulate cannabis use, with the clearest pathway via a part of section 51, which relates to copyrights, patents of inventions and designs, and trademarks.

Whether or not that proves to be a viable path to adult-use legalization in Australia is something that we will all have to wait and see. Even if there is a viable path to legalization in Australia, and the other claims by The Greens are accurate regarding federal law versus local law, the political will to pass a legalization measure still has to be in place, and that is likely not the case right now, unfortunately.

According to a poll conducted earlier this year by Essential Research, 55% of voters in Australia want cannabis to be legalized and regulated like alcohol. It’s a public policy and industry approach that is already working in Uruguay and Canada, as well as at the state-level in the United States.


university of sydney australia

University Of Sydney To Offer Free Cannabis Testing

The University of Sydney is launching a fairly robust study in an attempt to, as the university describes it, “investigate cannabis consumption, behaviours and attitudes among users.” Part of the study involves offering free, anonymous cannabis testing for people that cultivate their own cannabis in the Australian Capital Territory (ACT).

Cannabis was decriminalized in 2020 in the ACT and the university is researching any societal issues that may have arisen from the public policy change, as well as gain insight into the potency and varieties of cannabis that patients and consumers are using.

Free cannabis testing is available to both medical patients and non-medical patients, although only people that are current residents of the ACT can participate.

“The cannabis collected from growers’ homes will be analysed for cannabis content, including its main psychoactive components – tetrahydrocannabinol (THC) and non-intoxicating cannabidiol  (CBD) –  as well as a range of other cannabinoids and biologically active molecules, free of charge.  Participants will be able to view, anonymously, the analysis results from their cannabis samples online.” the university stated in a news release.

Initial results from the University of Sydney study are expected to be released in early 2023 and will presumably be used by lawmakers and regulators to craft regional and national cannabis policies and industry regulations. International cannabis observers will likely also benefit from reviewing the results.

Studies like this one can be very insightful because it involves cannabis that is actually being cultivated and consumed by people in real life versus cannabis that is cultivated by the government that often does not resemble the cannabis that people are actually consuming. Results from the latter types of studies always have to be taken with a grain of salt.


gold coast city queensland australia

Queensland’s Cannabis Driving Laws Are Inhumane

It is no secret that people that consume cannabis are often subjected to an enormous amount of stigma, including and especially from a public policy standpoint. After all, a vast majority of public policies directed towards cannabis consumers initially arose out of anti-cannabis fearmongering. Cannabis consumers, even patients, are often labeled as ‘dangers to themselves and others’ and a prime example of that is on display in Queensland where any amount of THC in a person’s system is a punishable offense, even if the person is a registered medical cannabis patient.

To be clear, I am not advocating for anyone to be driving on a public roadway while under the influence of cannabis or anything else for that matter. No one should ever operate a motor vehicle while impaired from any substance at all, including cannabis. Every responsible cannabis consumer on the planet feels the same way. With that being said, just because someone has THC in their system does not automatically mean that they are impaired at the time of the detection of THC. Detecting actual cannabis impairment is far more complicated than that.

Public Policy Built On Junk Science

Queensland is an Australian state located in the continent’s northeast region. It’s the third most-populated state in Australia, and currently has the highest population growth rate. Queensland is also home to a growing population of registered medical cannabis patients. According to Queensland law, “A patient living in Queensland must access medicinal cannabis through a doctor who is authorised under the Special Access or Authorised Prescriber Scheme administered by the Commonwealth Therapeutic Goods Administration (TGA).”

Unfortunately, any person that consumes any amount of cannabis, even when consumption is in line with TGA guidelines, essentially gives up their right to drive in Queensland due to how their current law is written and how long cannabis stays in a person’s system. Whereas many substances only stay in a person’s system for hours or days, THC can stay in a person’s system for much longer. In fact, one study found that THC could be detected in a person’s system for as long as 100 days after the person quit consuming cannabis.

Obviously, if a person consumed cannabis over three months ago they are not going to still be impaired today. Furthermore, it’s quite possible that they were not even impaired when they last consumed cannabis. Cannabis impairment depends on a number of factors including potency, tolerance level, form of consumption, and the amount of consumption. Someone that has consumed cannabis for a long time will build up a considerable amount of THC in their system while simultaneously having a tolerance that is so great that true impairment rarely occurs. That creates a situation in which the cannabis consumers that are least impaired are the ones most likely to have THC in their systems for longer durations of time, and public policy needs to account for that scientific fact.

Increase in ‘Drug-Driving’ Offenses

While more people are consuming medical cannabis in Queensland, completely legal consumption I will add, more people are also being charged with driving under the influence for cannabis in Queensland. Given the readily available science that clearly demonstrates how fast ‘active THC’ is metabolized by the human body (1-4 hours) and how long ‘metabolized THC’ can stay in the human body (up to 100 days), there’s almost always a viable defense for a cannabis DUI charge. However, that defense can only be successfully deployed after the person is subjected to inhumane treatment, including but not limited to: arrest, incarceration, fines, lost wages, lost employment, and public shaming.

Fortunately, lawmakers in Queensland are reviewing the state’s cannabis impairment laws and hopefully they will arrive at the logical conclusion that a zero tolerance policy towards metabolized THC is inhumane and ineffective. The only purpose it serves is to subject cannabis users to selective enforcement and the criminal justice system, and no suffering patient should ever have to endure such things. Again, I am not advocating for medical cannabis patients to be able to operate a motor vehicle on a public roadway while under the influence of cannabis, however, that needs to be balanced with implementing public policy that is based on science and not reefer madness fear mongering.

australia, queensland

  • 1
  • 2
International Cannabis Business Conference



© International Cannabis Chronicle. All rights reserved. Site developed and hosted by Rogue Web Works.